^
    Back
    Association details:
    Biomarker:EGFR wild-type + Chr 9q21.31-q22.2
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Pharmgenomics Pers Med
    Title:

    Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer

    Published date:
    09/19/2023
    Excerpt:
    Additionally, independent prognostic significance for OS in EGFR wild-type patients was observed for CNVs in 9q21.31-q22.2 and 11p11.11-q12.1 regions (P = 0.001). Patients with gains in these regions experienced extended OS, while losses were predictive of poorer outcomes.
    DOI:
    10.2147/PGPM.S418320